Table OF Content : 2 . Executive Summary
Antiandrogens- Expanding Role of new Oral Antiandrogens in early treatment armamentarium of Prostate Cancer and Other indications-
‣ Current Role of Oral antiandrogen therapy and its limitations
o nmCRPC and HSPC- Next growth driver of New Oral Antiandrogens – 509 or Xtandi or ODM-201- Who will win the race ?
ARN-
o WW Targeted Patient population and expected Market size expansion of Anti androgens in each stage
o Zytiga patent expiry – Game Changer in Antiandrogen Class o New Pipeline early stage Antiandrogens
‣ Targeting Xtandi and Zytiga Resistance population- A way to Fast track drug development ?
Ask for Discount @ https :// marketreportscenter . com / requestdiscount / 505877
Immuno-Oncology drug – Potential in Prostate Cancer and ongoing combination studies with Antiandrogens & with Pipeline Prostate Cancer drugs
Other Late stage Pipeline drugs for treatment of Prostate Cancer- AKT inhibitors or PARP inhibitors or a new MoA combination with Antiandrogen- Competing to Xtandi / Zytiga or targeting Xtandi / Zytiga Resistance Population ?
3 . Prostate Cancer
‣ Stages of prostate cancer
‣ Signs and symptoms of prostate cancer
‣ Causes of prostate cancer
‣ Treatment of prostate cancer
‣ Unmet need of prostate cancer